- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 2893778-31-7] PHGDH-IN-3
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-148570 |
| Brand: | MCE |
| CAS: | 2893778-31-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 495.55 |
| Molecular Formula | C24H18FN3O4S2 |
| SMILES | CC(C1=CC=CC(NS(=O)(C2=CC=C(C=C2)C(NC3=NC(C4=CC=CC(F)=C4)=CS3)=O)=O)=C1)=O |
Summary
PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC 50 value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer [1] .
In Vitro
PHGDH-IN-3 (compound D8) has good enzymatic inhibitory activity with an IC
50
value of 2.8 μM
[1]
.
PHGDH-IN-3 has high binding affinity for the PHGDH protein with a K
d
value of 2.33 μM
[1]
.
PHGDH-IN-3 has sensitivity to the cell lines with the PHGDH gene amplification or overexpression
[1]
.
PHGDH-IN-3 can restrict the de novo serine synthesis from glucose within MDA-MB-468 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PHGDH-IN-3 (compound D8) (p.o., i.v.; 1, 3 mg/kg) exhibits excellent in vivo pharmacokinetic properties
[1]
.
PHGDH-IN-3 (i.p.; 12.5, 25, 50 mg/kg; once daily for consecutive 31 days) exertes evident antitumor efficacy in the PC9 xenograft mouse model
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | ICR mice [1] | |||||||||||||||||||||
| Dosage: | 1, 3 mg/kg | |||||||||||||||||||||
| Administration: | Oral (p.o.) and intravenous (i.v.) administration | |||||||||||||||||||||
| Result: |
|
| Animal Model: | Balb/c nude mice [1] |
| Dosage: | 12.5, 25, 50 mg/kg |
| Administration: | Intraperitoneal (i.p.); once daily for consecutive 31 days |
| Result: |
Exhibited an in vivo anti-tumor effect and significantly delayed the tumor growth.
Significantly abated the tumor weights of mice at 25 mg/ kg. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.